Skip Navigation

A Randomized Phase II Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where cisplatin-Based Treatment is Not an Option

Brief Summary

Urologic / Genitourinary - Other

Study Type:

II Identifier:

Study #:

Start Date:
May 27, 2019

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT03237780

View Complete Trial Details & Eligibility at